THERMOGENESIS INITIATES SHIPMENTS OF THROMBIN PROCESSING DEVICES (TPD) TO BIOMET
ThermoGenesis Corp. (Nasdaq: KOOL) announced today that the Company has begun shipping its CE marked TPD to the Biomet, Inc. (Nasdaq: BMET) subsidiary, Cell Factor Technologies, Inc. (CFT). CFT will use the TPD to prepare autologous thrombin while a customized centrifugal thrombin device, named Clotalyst(TM), is under development by ThermoGenesis. The TPD disposable kit, which produces stable, activated thrombin from the patient's own blood in less than 30 minutes, will enable CFT to immediately address this demand in Europe, Canada, and Asia. Approximately $180 million of thrombin annually is consumed worldwide as a blood-clotting enzyme that surgeons use for hemostasis, the treatment of pseudoaneurysms, and to form "platelet gels" for the treatment of damaged tissue.